hematopoiet
cell
transplant
hct
cure
children
adult
sickl
cell
diseas
outcom
histor
poor
vast
major
patient
lack
match
sibl
donor
howev
develop
haploident
hct
haplohct
high
dose
posttranspl
cyclophosphamid
ptci
allow
cur
longterm
potenti
favor
transplantrel
outcom
though
obviat
potenti
graft
reject
human
leukocyt
antigen
mismatch
repeat
red
blood
cell
transfus
accordingli
multipl
strategi
develop
improv
outcom
major
base
john
hopkin
platform
present
aim
discuss
result
pertin
studi
compar
outcom
two
recent
approach
involv
either
thiotepa
plu
total
bodi
irradi
total
bodi
irradi
direct
comparison
requir
determin
optim
cur
potenti
transplantelig
patient
must
refer
tertiari
medic
center
consider
haplohct
sickl
cell
diseas
lifethreaten
hemoglobinopathi
lead
poor
qualiti
expect
life
children
adult
condit
caus
singl
missens
mutat
codon
six
beta
globin
gene
result
increas
clump
hemoglobin
red
blood
cell
particularli
condit
low
oxygen
tension
chronic
hemolysi
small
larg
vessel
highlight
pathophysiolog
clinic
manifest
highli
variabl
patient
includ
debilit
pain
vasoocclus
crise
stroke
associ
disabl
cardiopulmonari
abnorm
vision
impair
priapism
male
chronic
kidney
diseas
hepatobiliari
diseas
osteonecrosi
long
bone
splenic
infarct
overal
increas
risk
infect
complic
sickl
cell
diseas
also
neg
impact
healthcar
system
term
cost
work
product
result
mental
physic
disabl
current
manag
strategi
commonli
hydroxyurea
red
blood
cell
transfus
therapi
well
crizanlizumab
lglutamin
diseas
modifi
rather
cur
associ
uniqu
challeng
often
potenti
multiorgan
system
diseas
gene
therapi
shown
success
though
avail
broad
scale
associ
potenti
sever
toxic
result
condit
present
incur
without
allogen
hematopoiet
cell
transplant
hct
histor
optim
hctrelat
outcom
seen
children
receiv
myeloabl
condit
regimen
follow
infus
marrow
allograft
human
leukocyt
antigen
hla
match
relat
donor
cumul
data
children
age
year
underw
match
relat
donor
hct
notabl
sickl
cellfre
surviv
transplantrel
mortal
incid
acut
chronic
graft
versu
host
diseas
gvhd
less
respect
graft
reject
rate
less
howev
patient
chanc
match
sibl
donor
ethnic
minor
chanc
find
fulli
match
unrel
donor
unit
state
registri
mean
patient
inelig
cur
therapi
therebi
necessit
develop
altern
donor
platform
success
wide
adopt
altern
donor
approach
cure
sickl
cell
diseas
involv
haploident
graft
famili
donor
share
hla
loci
definit
haploidenticalhct
haplohct
provid
nearunivers
donor
avail
transplantelig
patient
though
histor
limit
due
high
transplantrel
mortal
pioneer
work
druginduc
immunolog
toler
administr
high
dose
posttranspl
cyclophosphamid
ptci
mitig
sever
acut
chronic
gvhd
reduc
though
elimin
graft
reject
problem
sever
patient
transfusiondepend
hemoglobinopathi
due
alloimmun
recurr
transfus
fig
accordingli
want
share
progress
ptcybas
haplohct
platform
emphasi
compet
strategi
improv
transplantrel
outcom
includ
graft
reject
relev
articl
obtain
extens
pubm
medlin
search
use
follow
keyword
phrase
sickl
cell
diseas
haploident
posttranspl
cyclophosphamid
graft
reject
thiotepa
total
bodi
irradi
clinicaltri
websit
wwwclinicaltrialsgov
also
search
use
keyword
major
haplohct
strategi
base
variat
protocol
creat
john
hopkin
univers
administr
ptci
day
posthaplohct
induc
favor
rate
gvhd
graft
reject
patient
hematolog
malign
though
first
shown
effect
also
individu
inherit
genet
disord
seventeen
patient
screen
enrol
consid
elig
median
age
year
condit
regimen
reduc
intens
includ
cyclophosphamid
fludarabin
rabbit
antithymocyt
globulin
total
bodi
irradi
depict
fig
except
thiotepa
patient
receiv
granulocyt
colonystimul
bone
marrow
allograft
follow
gvhd
prophylaxi
ptci
sirolimu
mycophenol
mofetil
fig
result
favor
transplantrel
mortal
seen
addit
patient
full
myeloid
chimer
sirolimu
last
followup
howev
graft
reject
occur
patient
reflect
inher
alloreact
clinic
fulli
engraft
experienc
resolut
vasoocclus
indic
import
mitig
graft
reject
improv
transplantrel
outcom
despit
high
graft
reject
rate
bolanosmead
et
al
demonstr
less
toxic
nonmyeloabl
regimen
haploident
graft
ptci
could
revers
sickl
cell
diseas
phenotyp
fitzhugh
colleagu
sought
improv
elig
haplohct
enrol
adult
multipl
comorbid
earli
phase
studi
alemtuzumab
total
bodi
irradiationbas
condit
follow
infus
granulocyt
colonystimul
factorprim
peripher
blood
allograft
tabl
twentyon
includ
patient
sickl
cell
diseas
two
transfusiondepend
betathalassemia
median
age
year
particip
split
three
cohort
differ
dose
ptci
given
ptci
mgkg
mgkg
respect
goal
determin
benefit
cyclophosphamid
improv
engraft
rate
patient
grade
moderatetosever
acut
gvhd
sever
chronic
gvhd
like
reflect
ptci
reduc
alloreact
furthermor
nonbeta
thalassemia
patient
surviv
though
patient
reject
die
engraft
rate
chimer
highest
cohort
three
though
reject
still
one
potenti
explan
condit
regimen
skew
toward
toler
rather
recipi
immunoabl
given
advanc
age
increas
number
comorbid
adult
patient
saraf
et
al
also
sought
determin
optim
condit
regimen
boost
engraft
use
peripher
blood
stem
cell
author
conduct
singleinstitut
retrospect
studi
patient
rang
year
first
two
receiv
regimen
develop
fitzhugh
et
al
remain
eight
receiv
bolanosmead
et
al
protocol
total
bodi
irradi
rather
gy
initi
studi
result
provid
evid
multiag
cytotoxicbas
regimen
rather
nonchemotherapybas
regimen
alon
first
two
patient
engraft
remain
patient
long
term
donor
cell
chimer
year
one
case
secondari
graft
reject
occur
rate
moderatetosever
acut
gvhd
extens
chronic
gvhd
respect
base
find
suggest
increas
dose
total
bodi
irradi
may
contribut
improv
engraft
albeit
cost
increas
acut
chronic
gvhd
bolanosmead
et
al
protocol
util
nonmyeloabl
condit
spare
toxic
wiebk
et
al
administ
myeloabl
regimen
alemtuzumab
fludarabin
treosulfan
thiotepa
cyclophosphamid
goal
ablat
recipi
immun
system
reduc
graft
reject
tabl
notabl
individu
receiv
total
bodi
irradi
three
patient
age
rang
year
includ
diseas
refractori
hydroxyurea
result
favor
term
absenc
graft
reject
full
donor
chimer
absenc
diseaserel
symptom
gvhd
month
posthaplohct
respect
small
sampl
size
limit
generaliz
warrant
valid
larger
prospect
clinic
trial
result
highlight
impact
total
bodi
irradi
longterm
outcom
pawlowska
colleagu
retrospect
assess
pretranspl
immun
suppress
two
cours
fludarabin
dexamethason
prior
haplohct
ptci
tabl
four
patient
median
age
year
receiv
reduc
intens
condit
rabbit
antithymocyt
globulin
busulfan
fludarabin
without
total
bodi
irradi
surviv
median
followup
month
part
due
donor
engraft
moderatetosever
acut
extens
chronic
gvhd
grade
note
tabl
addit
two
four
patient
note
high
antihla
titer
plasmapheresi
intraven
immun
globulin
rituximab
given
desensit
prior
condit
regimen
result
suggest
novel
approach
pretranspl
immun
suppress
investig
patient
addit
result
demonstr
desensit
benefici
patient
lack
better
donor
option
improv
enrol
transplantelig
individu
sickl
cell
diseas
improv
generaliz
find
intern
teambas
learn
collabor
establish
center
unit
state
unit
kingdom
franc
focu
haplohct
group
hypothes
nonmyeloabl
condit
addit
thiotepa
follow
infus
marrow
allograft
ptcybas
gvhd
prophylaxi
regimen
would
reduc
graft
reject
improv
transplantrel
outcom
fig
elig
criteria
similar
aforement
studi
includ
patient
year
age
least
one
criteria
sever
diseas
includ
cerebrovascular
event
last
longer
hour
author
year
graft
sourc
condit
regimen
nage
rang
os
n
gvhd
n
engraft
n
sickl
cellrel
transplant
outcom
bolanosmead
et
al
note
thank
editor
care
review
articl
tabl
share
similar
aforement
publish
work
name
patel
et
al
magnet
reson
imag
evid
stroke
recurr
acut
chest
syndrom
vasoocclus
crise
repeat
hospit
stay
chronic
lung
condit
includ
particip
favor
perform
statu
must
match
donor
phase
ii
studi
conduct
de
la
fuent
et
al
primari
end
point
eventfre
surviv
includ
primari
secondari
graft
reject
stroke
death
tabl
eighteen
patient
median
age
year
includ
first
three
receiv
john
hopkin
platform
remain
receiv
thiotepa
condit
due
graft
reject
seen
initi
patient
greater
myeloid
engraft
note
least
month
followup
patient
graft
reject
detect
patient
aliv
studi
complet
gvhd
rate
favor
acut
extens
chronic
gvhd
note
addit
precondit
appear
impact
transplantrel
outcom
patient
receiv
thiotepa
importantli
patient
immunosuppress
year
followup
find
indic
potenti
singl
dose
thiotepa
improv
efficaci
haplohct
base
improv
engraft
compet
strategi
improv
engraft
total
bodi
irradi
bolanosmead
et
al
sought
improv
main
problem
primari
graft
reject
note
initi
report
increas
dose
total
bodi
irradi
nonmyeloabl
condit
regimen
cgi
cgi
transplantelig
patient
sever
hemoglobinopathi
phase
ii
clinic
trial
condit
regimen
gvhd
prophylaxi
regimen
otherwis
primari
object
assess
engraft
base
donor
chimer
notabl
new
end
point
howev
enrol
stop
follow
recruit
particip
fund
stop
particip
enrol
sickl
cell
diseas
betathalassemia
major
children
adult
includ
median
age
year
rang
year
engraft
result
favor
full
myeloid
chimer
mix
chimer
primari
graft
failur
continu
benefit
ptci
gvhd
outcom
seen
evidenc
particip
grade
ii
acut
gvhd
grade
iii
diseas
particip
grade
iv
acut
gvhd
eighteen
percent
develop
limit
chronic
gvhd
importantli
time
last
followup
particip
document
gvhd
none
immunosuppress
therapi
sickl
cell
diseas
lead
agedepend
chronic
organ
dysfunct
result
decreas
surviv
affect
individu
main
limit
applic
hct
princip
donor
avail
toxic
condit
initi
approach
use
combin
recipi
immunoabl
condit
chemotherapi
total
bodi
irradi
appear
toxic
thu
affect
individu
candid
myeloabl
condit
due
age
comorbid
includ
dose
issu
relat
renal
hepat
dysfunct
risk
infertil
especi
younger
patient
fear
develop
acut
chronic
gvhd
remain
one
reason
patient
famili
declin
potenti
cur
therapi
nonmyeloabl
haplohct
appear
address
limit
factor
sinc
multipl
approach
util
combat
primari
issu
associ
haplohct
ptci
regimen
name
graft
reject
partial
inher
high
degre
alloreact
set
hla
mismatch
compound
alloimmun
high
number
transfus
notabl
patient
de
la
fuent
et
al
studi
comorbid
baselin
name
moyamoya
cerebrovascular
infarct
acut
chest
syndrom
compar
bolanosmead
et
al
studi
incid
moderatetosever
acut
gvhd
subsequ
chronic
gvhd
also
greater
particip
receiv
higher
dose
total
bodi
irradi
regimen
compar
term
graft
reject
overal
surviv
encourag
term
increas
futur
enrol
patient
trial
ultim
regimen
contain
thiotepa
plu
total
bodi
irradi
total
bodi
irradi
without
thiotepa
must
compar
head
head
prospect
random
trial
know
optim
approach
cure
patient
author
compet
interest
disclos
